3 Healthcare Stocks Getting Hammered

GEMP and ONCE are two of the worst stocks on the Nasdaq today

Managing Editor
Aug 7, 2018 at 2:30 PM
facebook X logo linkedin


Stocks are vaulting higher today thanks to a fresh batch of corporate earnings. It's not all positive news, though, and stocks careening lower include biotech Gemphire Therapeutics (NASDAQ:GEMP), gene therapy specialist Spark Therapeutics Inc (NASDAQ:ONCE), and medical device maker Orthofix Medical Inc (NASDAQ:OFIX). Here's a closer look at what's driving shares of GEMP, ONCE, and OFIX today.

FDA Request Sends GEMP Stock Reeling

At last check, Gemphire Therapeutics stock was down 52.9% to trade at $3.46, the second-worst stock on the Nasdaq today, after the Food and Drug Administration (FDA) asked for more safety data concerning the company's cholesterol drug, gemcabene. A hold is placed on any further studies until that data is provided. This is easily GEMP's worst day in history, and the stock earlier hit a new record low of $3.10. 

Despite the security's historical volatility, analysts remain committed to the drugmaker. All three of the brokerages covering GEMP rate it a "buy" or "strong buy," and its average 12-month price target of $26.50 is more than triple yesterday's closing perch of $7.34. However, Raymond James just downgraded the shares to "market perform" from "outperform."

Citi Still A Fan Of ONCE Stock Despite Subpar Earnings

Spark Therapeutics stock is down a 28% to trade at $55.85, also putting it near the bottom of the Nasdaq today, after the company announced lackluster trial data for the firm's hemophilia drug. In addition, the drug company reported a second-quarter earnings and revenue miss. Leerink responded by slashing its price target to $55 from $74, while Citi upgraded the equity to "buy" from "hold," finding positives from the hemophilia update. ONCE has now shed 73% since a July 9 all-time high of $96.59. 

Although the stock is on the short-sale restricted (SSR) list today, short sellers are likely cheering. The 5.34 million shares sold short represents 17% of ONCE's total available float, and 11.2 times the average daily trading volume.

OFIX Stock Tanks After Earnings, Slashed Guidance

Orthofix Medical stock is down 15.9% to trade at $52.01 after the company reported second-quarter revenue below analyst estimates, while also slashing its full-year guidance. Jefferies issued a price-target cut to $69 from $72 in response, and the stock is on track for its worst day since 2013. Nevertheless, OFIX scored a record high of $61.98 just yesterday, and still boasts a 16% lead year-over-year. Analysts are firmly entrenched in the bullish camp. All five of the brokerages covering OFIX rate it a "strong buy," while its average 12-month price target of $66.83 is a 29% premium to its current price.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI